Dong-A ST

Dong-A ST's Cheonan plant, a Korean pharmaceutical manufacturer, faced persistent operational challenges rooted in manual, paper-based production processes and fragmented data visibility across the facility. In pharmaceutical manufacturing, where Good Manufacturing Practice (GMP) compliance and full batch traceability are regulatory requirements, relying on manual records creates significant exposure — audit failures, batch release delays, and deviation handling bottlenecks. Without real-time production data, plant managers had limited ability to identify process deviations as they occurred, forcing reactive rather than preventive quality management. The status quo carried material risk to both regulatory standing and production throughput.

Dong-A ST partnered with Rockwell Automation to implement a Manufacturing Execution System (MES) and integrated automation platform at the Cheonan facility. Rockwell Automation's FactoryTalk PharmaSuite — their purpose-built MES for life sciences — was deployed to replace manual batch records and disconnected production tracking with a unified, electronic system. The platform connected shop-floor automation equipment to centralized production management, enabling electronic batch records (eBR), real-time work-in-progress visibility, and automated deviation capture. Integration with existing control infrastructure allowed the facility to digitize production workflows without wholesale replacement of prior automation investments, reducing deployment risk. Rockwell's domain expertise in pharmaceutical compliance guided the implementation to align with 21 CFR Part 11 and GAMP requirements.

Following deployment, the Cheonan plant achieved measurable improvements in both production efficiency and regulatory compliance posture. Key outcomes included:

• Elimination of paper batch records, reducing manual data entry and associated transcription errors
• Real-time production visibility enabling supervisors to monitor line status, batch progress, and deviations without manual reporting cycles
• Accelerated batch release processes through electronic batch record review, compressing release timelines
• Stronger audit readiness with complete electronic audit trails replacing manual documentation

Qualitatively, operators gained structured, step-by-step electronic work instructions, reducing reliance on tribal knowledge and improving process consistency across shifts.

• Start with compliance as the business case: In pharmaceutical manufacturing, MES implementations that target GMP and electronic batch record requirements deliver near-immediate risk reduction alongside efficiency gains.
• Integration with existing automation is achievable: Dong-A ST's deployment shows that MES can connect to existing plant-floor systems rather than requiring greenfield infrastructure.
• Electronic batch records change operator workflows significantly: Plan for change management and training investment proportional to how paper-dependent current processes are.
• Purpose-built pharma MES reduces validation burden: Vendor-supplied validation packages for life sciences MES platforms can materially shorten the IQ/OQ/PQ cycle.
• Visibility precedes optimization: Real-time production data is a prerequisite for any subsequent analytics or AI-driven process improvement initiative.